Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share in the recurrent setting, relegating the combination of Eisai’s Lenvima/Kisplyx with Novartis’s Afinitor, Pfizer’s Inlyta, and single-agent mTOR inhibitors to later lines. In the first-line setting, the entry of Exelixis/Ipsen’s Cabometyx—and regimens that combine immune checkpoint inhibitors with angiogenesis inhibitors—look set to revolutionize the treatment of advanced disease. Following Sutent’s approval for high-risk early-stage (stage I-III) patients in the United States, multiple immune checkpoint inhibitors are anticipated to launch for early-stage treatment. Despite the increasing number of agents being approved for renal cell carcinoma, the substantial unmet need that remain means that developers of therapies that are more efficacious and/or safer than the current standards of care could reap high commercial rewards.

Questions Answered:

  • How large are the early-stage and advanced or metastatic renal cell carcinoma drug-treatable populations? Will drug-treatment rates change over time?
  • How is renal cell carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • Who are the key players developing combination therapies for renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
  • Which emerging therapies we forecast will enter each of the renal cell carcinoma market segments? What uptake and sales are these therapies anticipated to secure?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).

Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.

Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.

Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.

Emerging therapies: Phase III: 7 drugs; Phase II: 20 drugs; coverage of select Phase I and preclinical products.


Related Reports

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma | Disease Landscape and Forecast | G7 | DLSFON0009-2020

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Emerging Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of...

View Details

Renal Cell Carcinoma - Epidemiology - Epidemiology Dashboard

DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence...

View Details